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Abstract: Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal disorders. Diagnosis can be challenging 
as more than 40 genes are known to cause non-syndromic RP and phenotypic expression can differ significantly resulting 
in variations in disease severity, age of onset, rate of progression, and clinical findings. We describe the clinical 
manifestations of RP, the more commonly known causative gene mutations, and the genotypic-phenotypic correlation  
of RP. 
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INTRODUCTION 
  Retinitis pigmentosa (RP) represents a heterogeneous 
group of inherited retinal dystrophies characterized by 
abnormalities of photoreceptors and retinal pigment 
epithelium that lead to progressive retinal degeneration, 
atrophy and ultimate visual loss. RP affects 1 in 3500 to 
5000 people worldwide [1, 2]. Classification of retinitis 
pigmentosa reveals two main groups: “typical” or “non-
syndromic” RP in which disease manifestations are confined 
to the eye and “complicated” or “syndromic” RP in which 
patients have associated non-ocular findings. The latter 
group includes Usher syndrome, Bardet-Biedl syndrome, 
Refsum syndrome, Neuronal ceroid lipofuscinosis or Batten 
disease, Alstrom disease, Bassen-Kornzweig syndrome, 
Kearns-Sayre syndrome, and Mucopolysaccharidoses [1]. 
The differential diagnosis of retinitis pigmentosa is vast, and 
the combination of multiple causative genes and broad range 
of clinical severity has made both diagnosis and prognosis 
challenging. Herein, we discuss the genotypic multiplicity 
and phenotypic variability found in typical or non-syndromic 
retinitis pigmentosa. 
CLINICAL MANIFESTATIONS AND PHENOTYPIC 
VARIABILITY 
  Retinitis pigmentosa is characterized by nyctalopia, 
constricted visual fields, bone spicule pigmentation of the 
fundus, and photoreceptor cell dysfunction. Clinical 
presentation and severity varies with inheritance pattern. 
Individuals with X-linked RP generally present early 
whereas those with autosomal dominant RP have a later 
onset. The same genetic mutation can also produce variable 
expression patterns not only between families, but also 
within families. Incomplete penetrance and variable   
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expressivity may be due to interactions between genes or 
their environment as there are many factors that can interfere 
with gene expression from transcription to protein activation. 
Ocular Manifestations 
  Funduscopic findings include arteriolar narrowing, fine 
intraretinal pigmentation, and loss of retinal pigment 
epithelium (RPE) typically in the mid- and far-periphery. 
With progression of primarily rod photoreceptor 
degeneration, there is increasing loss of RPE pigment with 
intraretinal clumping of melanin appearing as coarse clumps 
in the classic bone spicule configuration [1]. With time, 
retinal vascular attenuation and waxy pallor of the optic 
nerve become more apparent. Occasionally, deep white dots 
at the level of the RPE, secondary to nonspecific pigment 
epithelial degeneration, arise, a feature of retinitis punctata 
albescens [1]. In typical RP, the central retina is relatively 
spared until very advanced stages with the onset of foveo-
macular atrophy. 
  In the vitreous, fine colorless particles comprised of free 
melanin pigment granules, pigment epithelium, uveal 
melanocytes, and macrophage-like cells may occur usually 
early in the course of typical RP before funduscopic changes 
are clinically apparent [1]. Optic nerve head drusen are also 
common without any diagnostic or prognostic significance. 
Later manifestations of RP include cataract, usually a central 
posterior sub-capsular type with a clear nucleus. 
Symptomatically, it tends to obstruct the central visual field 
and exacerbate photophobia. Central visual acuity can also 
be affected due to macular edema, the result of intracellular 
swelling of Müller cells and breakdown of the blood-retinal 
barrier. Patients with advanced RP can also develop pseudo-
Coats’ disease, a peripheral exudative vasculopathy 
associated with telangiectatic vessels, serous retinal 
detachment, and retinal lipid deposition. 
  Both eyes are comparably affected along a phenotypic 
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with normal fundus findings and photoreceptor degeneration, 
to sector RP affecting 1-2 quadrants (usually infero-nasal) of 
the fundus, to diffuse retinal pigmentary changes. 
Visual Field 
  Progressive loss of peripheral visual field is characteristic 
of RP. Visual field testing is a subjective examination 
mapping one’s central and peripheral vision. Kinetic 
perimetry, such as Goldmann visual field testing, utilizes a 
moving test target of variable size against a uniformly 
illuminated background and tests out to 90
o temporally. In 
early RP, there is a patchy mid-peripheral field loss 20-25
o 
from fixation. With disease progression, a mid-peripheral 
ring scotoma develops and enlarges more rapidly toward the 
periphery than centrally [1]. 
Dark Adaptation 
  Dark adaptation testing is useful in the evaluation of 
nyctalopia, which occurs early in RP. Recovery of 
photoreceptor sensitivity after light exposure is dependent on 
the regeneration of bleached photo-pigments. After adapting 
to darkness, the sensitivity to light increases; that is, the 
threshold response to light decreases. Patients adapt to 30-60 
minutes of darkness and then detect the dimmest light 
possible. In normal dark adaptation the transition between 
the faster cone function and slower rod function, or cone-rod 
break, occurs after 5 minutes. Abnormalities associated with 
RP are variable and include a delayed cone-rod break, an 
elevated final threshold, and a prolonged recovery to final 
threshold. In advanced RP, the final rod threshold can be 3 
or more log units greater than normal [3, 4]. In individuals 
with rhodopsin mutations, the late rod portion of dark 
adaptation is affected, whereas early rod and cone adaptation 
are normal [4]. 
Visual Acuity 
  Visually acuity is usually maintained until very late in the 
course of RP unless macular atrophy or cystoid macular 
edema is present. Visual acuity is variable, but in general 
vision loss is characterized as less severe in individuals with 
autosomal dominant RP than with autosomal recessive RP. 
Patients with X-linked RP typically have the worst visual 
prognosis [1, 5]. 
Color Vision 
  Macular cone function can be assessed with color vision 
testing. Deficiency in blue cone function (acquired 
tritanopia) is characteristic of advanced RP. Individuals with 
vision worse than 20/30 and areas of macular atrophy 
correspond to poorer performance on color vision tests such 
as the Nagel anomaloscope and Farnsworth-Munsell 100-hue 
test. Those with autosomal dominant RP correlate to better 
color vision testing than those with other inheritance types 
[5]. 
Electroretinography 
  Conventional or full-field electroretinography (ERG) 
objectively demonstrates the overall functional status of the 
photoreceptors by measuring retinal electrical potential after 
light stimulation. A dim blue light (dark adapted) single flash 
induces a rod response and a flickering (30 Hz) white light 
elicits a cone response. Early and severe impairment of pure 
rod responses occurs in RP with a dramatic decrease in 
amplitude and implicit times of both a-waves 
(photoreceptor) and b-waves (signaling by second-order 
bipolar cells). Advanced RP patients have extinguished rod 
and cone responses [1, 6]. 
  Whereas full-field ERG will reveal abnormalities when 
more than 20% of the retina is affected, multifocal ERG can 
localize affected areas of retinal dysfunction. In RP, 
multifocal ERG demonstrates a significant reduction in the 
paracentral retina compared to the central retina [7]. There is 
no correlation between multifocal ERG pattern and 
inheritance type [8]. 
Electro-Oculography 
  Electro-oculography (EOG) reflects a global outer retina 
and RPE function. When ERG findings are abnormal, EOG 
is also abnormal. In RP patients, its main utility may be in 
the evaluation of carriers with questionable funduscopic and 
ERG findings. In X-linked RP, EOG measurements are 
extinguished in RP patients and subnormal in RP carriers. 
EOG abnormalities have been found more often in RP 
patients over the age of 40 years [9]. 
Optical Coherence Tomography 
  Optical Coherence Tomography (OCT) is a non-invasive 
testing modality providing morphological information of the 
retina. It assesses the vitreoretinal interface, retinal contour 
and thickness, presence of intraretinal or subretinal fluid, and 
photoreceptor layer and RPE status. Compared to time-
domain OCT, Fourier-domain OCT provides greater axial 
resolution and scanning speed allowing for more detail of the 
structural changes within the retinal layers, specifically the 
outer segment, inner segment, outer nuclear layer, as well as 
the RPE. The relationship between retinal structure and 
visual function has been studied in RP patients utilizing 
Fourier-domain OCT and automated perimetry as well as 
microperimetry [10, 11]. In RP patients, photoreceptor 
thickness as demonstrated on OCT decreases with loss of 
visual field sensitivity [10]. 
  OCT is also useful as a screening tool in the detection of 
sub-clinical cystoid macular edema (CME) [12, 13]. Hajali et 
al. reported a 38% prevalence of CME in at least 1 eye. 
Although not statistically significant, the prevalence of CME 
was found to be 52% for autosomal dominant RP, 39% for 
autosomal recessive RP, 39% for isolated RP, and none for 
X-linked RP [13]. 
GENOTYPIC HETEROGENEITY IN RETINITIS 
PIGMENTOSA 
  The molecular genetics of retinitis pigmentosa are 
complex. RP is associated with an expanding number of 
newly identified gene mutations, which can be sporadic or 
familial with multiple modes of transmission. Genes 
associated with RP code for proteins that play important 
roles in phototransduction, the visual transduction cascade, 
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while many different genes may result in a similar disease 
phenotype, there is wide variation in phenotypic results 
within families sharing the same genetic mutation. RP has 
been associated with a variety of inheritance patterns and 
some genes may have more than 1 mode of transmission. 
Roughly 20-25% of cases are autosomal recessive, 15-20% 
of cases are autosomal dominant, 10-15% of cases are X-
linked, and the residual majority of cases making up 40-55% 
appear to be sporadic or are unable to be classified [2]. To 
date, 17 autosomal dominant, 24 autosomal recessive, and 6 
X-linked RP loci have been mapped [14]. Table 1 
summarizes the known genes implicated in RP [1, 2, 14-40]. 
AUTOSOMAL DOMINANT RP 
  Autosomal dominant retinitis pigmentosa represents 
approximately 15-20% of RP cases [2]. It is generally the 
least severe form of RP, with later onset and tendency to 
retain good visual acuity. The three most common gene 
mutations involved in autosomal dominant RP include RHO 
(rhodopsin),  RP1 (oxygen-regulated proteins), and RDS 
(RDS/Peripherin).  
RHO Mutations 
  Rhodopsin is a transmembrane photo-pigment located in 
the discs of rod photoreceptor outer segments. Rhodopsin is 
responsible for light absorption and initiation of the visual 
phototransduction cascade. Over 100 mutations in the 
rhodopsin gene (RHO) have been identified and linked to RP 
with over 30% of cases involving autosomal dominant RP 
[2, 41, 42]. Rhodopsin, a key transmembrane structural 
component, makes up approximately 85% of the protein 
content of rod photoreceptor outer segments [43]. It has three 
domains, the intradiscal, the transmembrane, and the 
cytoplasmic domain. Mutations have been identified in each 
of the three domains. Sandberg et al. linked RP phenotypic 
severity with the location of the rhodopsin mutation involved 
[44]. Patients with mutations in the intradiscal domain tend 
to have better visual prognosis than those with 
transmembrane domain mutations, while patients with 
cytoplasmic domain mutations have the worst visual 
function [44]. 
  The most common mutation in the rhodopsin gene found 
in the United States in the Pro23His mutation. This mutation 
is located on the rhodopsin intradiscal domain and accounts 
for 10-15% of autosomal dominant RP in American 
Caucasians [45]. The phenotype associated with the 
Pro23His mutation is relatively mild when comparing patient 
visual fields and ERG amplitudes [44, 46]. 
  Mutations found in the rhodopsin cytoplasmic domain 
carries a worse visual prognosis and more severe phenotype 
and may be due to the important cellular transport functions 
of this domain [2, 46]. In particular, several disease 
mutations have been found in the 347 codon of the rhodopsin 
cytoplasmic domain. These mutations, including the 
relatively common Pro347Leu mutation, have been 
associated with a comparatively poor visual prognosis [47]. 
RP1 Mutations 
 The  RP1 gene, located at 8q12.1, has been associated 
with approximately 5-10% of autosomal dominant retinitis 
pigmentosa cases [1]. Expression of RP1 appears to be 
regulated by retinal oxygen levels and has been shown to 
encode a photoreceptor protein involved in the correct 
stacking of photoreceptor outer segments [48, 49]. The gene 
contains 4 exons. Four RP1  mutations account for the 
majority of RP1 associated retinitis pigmentosa. These are 
R677X, Q679X, 2433del5bp, and 2435del4bp, with R677X 
and Q679X responsible for up to 60% of all RP1 mutations. 
All four of the major RP1 mutations result in truncation of 
the RP1 protein and cause photoreceptor degeneration. 
However, between families and individuals with the same 
mutation great variation in phenotypic manifestations exists, 
and environmental as well as genetic factors may be 
involved [2]. 
RDS Mutations 
 The  RDS gene located on chromosome 6p21.1-cen 
encodes for the protein peripherin, or RDS/Peripherin, and is 
responsible for an estimated 5-10% of autosomal dominant 
retinitis pigmentosa [1]. Studies have shown that 
RDS/Peripherin accumulates in the discs of photoreceptor 
outer segments and is important for photoreceptor structure 
and stability [50]. The RDS/Peripherin protein is made up of 
four transmembrane domains and three loops, with the most 
severe phenotypic variants arising from mutations within the 
intradiscal loop between the third and fourth transmembrane 
domains [51]. Mutations of RDS/Peripherin protein are 
numerous and associated with a wide range of phenotypes 
including other autosomal dominant macular dystrophies 
[52-56]. 
AUTOSOMAL RECESSIVE RP MUTATIONS 
  Autosomal recessive RP is the most common inherited 
form of the disease comprising 20-25% of cases. Autosomal 
recessive RP is often associated with earlier age of symptom 
onset and more severe phenotype than autosomal dominant 
RP. Most of the genes associated with autosomal recessive 
RP are very rare. Several of the more common gene 
mutations found in autosomal recessive RP include ABCA4, 
RPE65,  PDE6A and PDE6B, and USH2A, many of which 
are also associated with other autosomal recessive retinal 
disorders [1]. 
ABCA4 Mutations 
  The photoreceptor cell-specific ATP-binding cassette 
transporter (ABCA4) gene is located on chromosome 1p21-
p13 and has been implicated in up to 5% of autosomal 
recessive retinitis pigmentosa cases [57]. ABCA4 codes for 
an important transmembrane transport protein found in the 
discs of photoreceptor outer segments [58]. It is made up of 
6 transmembrane helices, an exocytoplasmic domain within 
the photoreceptor discs and a cytoplasmic domain. The 
normal ABCA4 transporter is thought to bind retinylidene-
phosphatidylethanolamine (N-retinylidene-PE) in the discs 
and transport it to the cytoplasmic side. Here N-retinylidene-
PE breaks down into all-trans-retinal, a form of vitamin A 
that can be used in the visual cycle [59]. ABCA4 mutations 
have been associated with autosomal recessive RP as well as 
Stargardt macular dystrophy, fundus flavimaculatus, cone 
rod dystrophy, and even some cases of age-related macular 
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Table 1.  Genes in Retinitis Pigmentosa 
Inheritance  Gene Symbol  Locus  Gene Name / Protein Name  Function 
AD  CRX  19q13.32  Cone-rod otx-like homeobox TF  Photoreceptor cell transcription factor 
AD   FSCN2  17q25  Retinal fascin homolog 2  Structure of photoreceptor cells 
AD  IMPDH1  7q32.1  Inosine monophosphate dehydrogenase 1  Regulation of cell growth 
AD  PRPF3/HPRP3  1q21.2     Pre-mRNA splicing factor 
AD  PRPF31/RP11  19q13.42     Pre-mRNA splicing factor 
AD  PRPF8  17p13.3     Pre-mRNA splicing factor 
AD  RDH12  14q24.1  Retinol dehydrogenase 12  Visual transduction cascade 
AD  ROM1  11q12.3  Rod outer-segment membrane protein1  Photoreceptor structure 
AD RP7/PRPH2  6p21.1  Peripherin  2  * 
AD RP7/RDS  6p21.2  Peripherin/RDS  Photoreceptor  structure 
AD RP9  7p14.3  RP9  protein  * 
AD   RP17/CA4  17q22  Carbonic anhydrase IV  Pre-mRNA splicing factor 
AD  RP31/TOPORS  9p21.1  Topoisomerase I binding protein  * 
AD RP33/SNRNP200  2q11.2  Small  nuclear  ribonucleoprotein  * 
AD  RP35/SEMA4A  1q22  Semaphorin 4A  Neuroretinal development 
AD  RP37/NR2E3  15q23  Nuclear receptor subfamily 2, E3  Transcription factor 
AD  RP42/KLHL7  7p15.3  Kelch-like 7 protein  Protein degradation 
AD  RP48/GUCA1B  6p21.1  Guanylate cyclase activating protein  * 
AD/AR  NRL  14q11.2  Neural retina lucine zipper  Photoreceptor cell transcription factor 
AD/AR  PDC  1q25-32.1     Visual transduction cascade 
AD/AR RHO/RP4/RP5  3q22.1  Rhodopsin  Phototransduction  cascade 
AD/AR  RP1  8q12.1     Photoreceptor transcription factor 
AD/AR  RP50/BEST1  11q12.3  Bestrophin  RPE transmembrane chloride channel 
AR  ABCA4  1p22.1  ATP binding cassette transporter  Catabolic functions in the retina 
AR  CERKL/RP26  2q31-q33  Ceramide kinase  Ceramide metabolism 
AR  CNGA1/RP49  4p12  Rod cGMP gated channel protein   Visual transduction cascade 
AR  CNGB1/RP45  16q13  Rod cGMP gated channel protein  Visual transduction cascade 
AR CRB1/RP12  1q31.3  Crumbs protein homolog 1  Transcription factor 
AR  IMPG2  3q12.3  Interphotoreceptor matrix proteoglycan 2  * 
AR  LRAT  4q32.1  Lecithin retinol acyltransferase  Retinoid metabolism 
AR MERTK/RP38 2q13  Mer  receptor  tyrosine  kinase  Disc  shedding 
AR  PDE6A/RP43  5q33.1  Rod cGMP phosphodiesterase   Visual transduction cascade 
AR  PDE6B/RP40  4p16.3  Rod cGMP phosphodiesterase   Visual transduction cascade 
AR  PDE6G  17q25.3  Rod cGMP phosphodiesterase   Visual transduction cascade 
AR  RBP3  10q11.22  Retinol binding protein 3  Retinoid transport 
AR  RGR/RP44  10q23.1  RPE-retinal G protein coupled receptor  Retinoid metabolism 
AR  RLBP1  15q26.1  Retinaldehyde-binding protein 1  Retinoid metabolism Diagnostic Challenges in Retinitis Pigmentosa  Current Genomics, 2011, Vol. 12, No. 4    271 
(Table 1). Contd….. 
Inheritance  Gene Symbol  Locus  Gene Name / Protein Name  Function 
AR RP22  16p12.1p12.1     * 
AR RP25  6cen-q15      * 
AR  RP28  2p16-p11  Family with sequence similarity 161, A  * 
AR RP29  4q32-q34      * 
AR RP32  1p21.2-p13.3     * 
AR  RP36/PRCD  17q25.1  Progressive rod-cone degeneration protein  * 
AR RP41/PROM1  4p15.32  Prominin  1  * 
AR  RP46/IDH3B  20p13  NAD(+) specific isocitrate dehydrogenase 3 B  * 
AR  RP51/TTC8  14q32.11  Tetratricopeptide repeat domain 8  * 
AR  RP54/C2ORF71  2p23.2  Chromosome 2 open reading frame 71  * 
AR RPE65/RP20  1q31.2  RPE65  Retinoid  metabolism 
AR  SAG/RP47  2q37.1  Rod arrestin  Visual transduction cascade 
AR  SPATA7  14q31.3  Spermatogenesis associated protein 7  * 
AR  TULP1/RP14  6p21.31  Tubby-like protein 1  Vesicular transport 
AR  USH2A/RP39  1q41  Usherin  Retinal development, cell adhesion 
AR  ZNF513  2p23.3  Zinc finger protein 513  * 
XL  RP2  Xp11.23  Homology with human cofactor C  Protein folding 
XL RP6  Xp21.3-21.2     * 
XL RP23 Xp22      * 
XL RP24  Xq26-27      * 
XL RP34  Xq28-qter      * 
XL RPGR/RP15  Xp21.1  Retinitis pigmentosa GTPase regulator  Protein transport 
*Function not fully identified. 
RPE65 Mutations 
 The  RPE65 gene has been associated with autosomal 
recessive retinitis pigmentosa as well as autosomal recessive 
Leber congenital amaurosis (LCA). RPE65 accounts for 
about 2% of all autosomal recessive RP and is responsible 
for 6-16% of cases of LCA. RPE65 is associated with 
metabolism of retinoids involved in the visual cycle [10]. 
X-LINKED MUTATIONS 
  X-linked retinitis pigmentosa accounts for approximately 
10 to 15% of all retinitis pigmentosa and tends to be the most 
severe form of the disease with the earliest onset and the 
most rapid progression. Affected males develop visual 
symptoms early in life, often manifesting symptoms of night 
blindness before age 20, progressing to significant visual 
impairment by the 4
th decade. Affected females usually have 
a less severe phenotype, likely due to random X-inactivation 
[2]. Two genes have been implicated in the majority of cases 
of X-linked retinitis pigmentosa, RPGR and RP2. 
RPGR Mutations 
  The retinitis pigmentosa GTPase regulator (RPGR) gene 
is located on chromosome Xp21.1 and accounts for 
approximately 70-90% of cases of X-linked RP [1]. RPGR is 
composed of 19 exons and codes for a protein made up of 
815 amino acids. To date, 77 gene mutations have been 
identified and are mainly localized in exons 1-14 and 
ORF15. Most of these mutations result in early termination 
of translation [2]. The function of RPGR is currently 
unknown, but gene products have thus far been associated 
with protein transport and intracellular trafficking. Mutations 
of  RPGR have been associated with a variety of diseases 
including X-linked recessive and X-linked dominant RP, as 
well as X-linked cone-rod dystrophy and X-linked macular 
degeneration [24]. Specific X-linked RP RPGR mutations 
are often found only in single families, making genotypic-
phenotypic correlations difficult [2]. 
RP2 Mutations 
 RP2 is located on chromosome Xp11.3 and accounts for 
roughly 10-20% of cases of X-linked RP [1]. The RP2 gene 
consists of 5 exons encoding a 350 amino acid protein. Most 
of the RP2 mutations commonly found in X-linked RP result 
in sequence truncation or missense mutations. According to 
a recent study by Jayasundera et al., RP2 mutations in X-
linked RP have been associated with patients of younger age, 
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similar to choroideremia without corresponding 
choroideremia gene mutations [61]. 
GENOTYPE-PHENOTYPE CORRELATIONS 
Age of Onset 
  Early onset RP is diagnosed around 2 years of age. The 
causative genes include RPE65, CRB1, and TULP1 [5, 62-
64]. Late onset RP, diagnosed when symptoms of RP 
develop in mid-life, is typically autosomal dominant in 
inheritance [2, 65]. The CRX gene is involved in late-onset 
autosomal dominant RP [66]. 
Fundus Appearance 
  In general absence or scarcity of pigment deposits is 
more frequent in individuals with myopia due to retinal 
pigment atrophy or RP sine pigmento and does not 
necessarily reflect the severity of disease [5]. Mutations in 
several genes are associated with specific fundus findings. 
Mutations in the RHO and PRPF31 genes are involved in 
sector RP [5, 67]. The CRB1 gene is associated with para-
arteriolar retinal pigment epithelium preservation [68]. 
Retinitis punctata albescens is seen in RLBP1 gene mutations 
[69]. Severe macular atrophy in RP involves RDS and CRX 
genes [5, 52]. A mutation in the CRB1 gene likely in 
association with other genetic or environmental factors has 
been found in individuals with Coats’-like exudative 
vasculopathy [70]. 
GENETIC TESTING IN RP 
  Genetic testing for RP could potentially provide more 
specific disease characterization and prognostic information. 
More importantly, gene-specific treatment is becoming more 
promising as seen with ongoing clinical trials for Leber 
Congenital Amaurosis [2, 71-73]. Molecular testing, 
however, remains to be defined in RP due to its genetic 
heterogeneity with no single mutation accounting for more 
than 10% of RP patients [2]. 
  Current conventional screening technology includes 
conformation sensitive gel electrophoresis, denaturing high 
performance liquid chromatography, and direct DNA 
sequencing. In cases of unknown inheritance pattern, current 
screening methods are costly, time-consuming, and labor-
intensive as it involves 500 exons consisting of over 120,000 
base pairs. Moreover, the rate of false positives is relatively 
high due to polymorphic variants. Thus, screening for 
patients with an unknown inheritance pattern is not a feasible 
or practical option. The task of screening individuals with a 
known inheritance pattern may be somewhat less arduous 
but remains inefficient. Screening for X-linked recessive RP 
involves 2 genes comprising of 24 exons with 7000 base 
pairs. Twenty genes comprised of 337 exons with 75,000 
base pairs are screened in autosomal recessive RP, the most 
common inheritance pattern, whereas 15 genes divided into 
135 exons and including 38,000 base pairs are screened in 
autosomal dominant RP [68]. Unfortunately, conventional 
screening is not 100% sensitive as some mutations go 
undetected. Furthermore, non-pathogenic DNA variations 
that lead to silent mutations or mutations that do not 
significantly alter the protein may be detected. 
  DNA micro-array technology, a high-throughput 
screening tool, uses a disease chip containing all known 
disease associated alleles [74-76]. It is faster, less costly, and 
theoretically can be updated to screen for new genes or 
mutations. Advantages of this technology compared to 
conventional techniques include the miniaturized size of the 
arrays and the ability to assess thousands of genes at one 
time with minimal tissue sample [77]. Furthermore, the large 
number of probes on a single micro-array slide can include 
replicates and controls to improve sensitivity, specificity, 
and accuracy. 
  Micro-array as a diagnostic screening tool is limited in 
that only known mutations are detected, thus overlooking 
rare and novel mutations. A significant number of RP cases 
are caused by deep intronic mutations, which would not be 
detected as well. Micro-array screening in combination with 
sequence analysis could potentially detect novel mutations 
[76, 78, 79]. With continued development, micro-array 
technology in RP could allow for accurate prognostic and 
therapeutic insights. 
  Currently, 42 genes can be tested by centers throughout 
the world for autosomal dominant, autosomal recessive, and 
X-linked RP. GeneTests provides a directory of these 
laboratories [http://www.ncbi.nlm.nih.gov/sites/GeneTests/ 
?db=GeneTests]. 
CONCLUSION 
  The correlation between genotype and phenotype is not 
completely evident in RP. Causative genes continue to be 
identified making diagnosis difficult. Moreover, the exact 
cause of penetrance and expressivity are still not well 
elucidated. Developing an adequate screening test especially 
without a known inheritance pattern will continue to remain 
a challenge. The importance cannot be understated as 
identification of these genes could potentially lead to novel 
treatments or gene therapy trials. 
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